FindTrial
Sign In

A Clinical trial to study role of probiotics on gut permeability and endotoxemia in patients with acute pancreatitis

Role of probiotics in preventing infectious complications in patients with acute pancreatitis: a randomized placebo controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2009/091/000933
Enrollment
100
Registered
2009-12-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Probiotics: Four sachets of probiotics per day for 7 days Control Intervention1: Placebo: Four sachet per day for 7 days

Sponsors

Anoop Saraya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with AP presenting within the first 72 hours after the onset of abdominal pain or have been nil orally at the time of presentation for up to 5 days.

Exclusion criteria

Exclusion criteria: (a) Malignancy ,(b) Infection or sepsis related to source other than pancreatic bed, (c) Intra-operative diagnosis of AP,(d) Immunodeficiency,(e) Prior use of probiotics or prebiotics, (f) Pregnant ladies.

Design outcomes

Primary

MeasureTime frame
Effect on gut permeability and endotoxemia via prevention of bacterial translocation and restoring the intestinal permeability.Timepoint: At baseline and day 7—

Secondary

MeasureTime frame
Clinical end point. Mortality, total hospital stay, duration of ICU stay, side effects Biochemical. (i) C-reactive protein (ii) Prealbumin Timepoint: Base line and day 7—

Countries

India

Contacts

Public ContactAnoop Saraya
ansaraya@yahoo.com011 26593294

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026